Anti-CD19-CAR / Beijing Doing Biomedical  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Anti-CD19-CAR / Beijing Doing Biomedical
NCT02546739: Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Not yet recruiting
1
100
RoW
Anti-CD19-CAR
Beijing Doing Biomedical Co., Ltd., The First Hospital of Jilin University, Hebei Yanda Ludaopei Hospital
Leukemia, Lymphoma
03/22
03/23

Download Options